InvestorsObserver is giving Relmada Therapeutics Inc (RLMD) an Analyst Rating Rank of 20, meaning RLMD is ranked higher by analysts than 20% of stocks. The average price target for RLMD is $7.083 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating RLMD a Buy today. Find out what this means to you and get the rest of the rankings on RLMD!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Relmada Therapeutics Inc Stock Today?
Relmada Therapeutics Inc (RLMD) stock is trading at $2.93 as of 1:02 PM on Monday, Sep 25, an increase of $0.14, or 5.02% from the previous closing price of $2.79. The stock has traded between $2.71 and $2.97 so far today. Volume today is below average. So far 132,668 shares have traded compared to average volume of 210,622 shares.
Click Here to get the full Stock Report for Relmada Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
